Dyno Therapeutics, a genetic technologies company, announced the launch of Dyno-yp2, a novel adeno-associated virus (AAV) gene delivery vector engineered for central nervous system delivery. According to the company, Dyno-yp2 is designed to bind the human transferrin receptor (hTfR1) to cross the blood-brain barrier and demonstrated high-performance results in preclinical testing.
In in vivo studies in TfR-humanized mice, Dyno-yp2 achieved over 94 percent neuronal transduction and an 11-fold improvement in brain biodistribution compared with a leading published comparator, the BI-hTFR1 capsid. The company said that the vector also showed substantial liver detargeting, with 80-fold reduction versus BI-hTFR1 and 29-fold reduction versus AAV9, indicating potent central nervous system transduction with reduced off-target exposure.
Dyno-yp2 was developed using the company’s artificial intelligence-driven platform, which integrates extensive in vivo data to optimize AAV capsids for blood-brain barrier crossing. The company claims this expands its suite of vectors for multiple delivery mechanisms, offering strategic delivery options for gene therapy developers.
The vector is available for licensing and for evaluation through Dyno’s Frontiers Program, which supports rapid in vivo testing of therapeutic payloads. According to the company, Dyno-yp2 complements its existing portfolio of capsids targeting muscle, neuromuscular, ocular and CNS applications, and reinforces its approach to addressing gene therapy delivery challenges.
